Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations

The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.